The Hetero Ring Has Exactly 13 Ring Carbons (e.g., Erythromycin, Etc.) Patents (Class 514/29)
-
Publication number: 20150087608Abstract: Methods and devices treating an autonomic nervous system associated disease condition in a subject are provided. Aspects of the invention include inducing one or more physiological response selected from the group consisting of sweating, gastric emptying, enhanced heart rate variability and enhanced quantitative sensory test responsiveness in a manner sufficient to modify the autonomic nervous system so as to treat the subject for the disease condition. The methods and devices find use in a variety of applications, e.g. in the treatment of subjects suffering from conditions arising from disorders of the autonomic nervous system.Type: ApplicationFiled: November 10, 2014Publication date: March 26, 2015Inventor: Anthony Joonkyoo Yun
-
Publication number: 20150071992Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.Type: ApplicationFiled: November 25, 2014Publication date: March 12, 2015Inventors: DAVID C. CIPOLLA, JAMES BLANCHARD
-
Patent number: 8962021Abstract: This invention relates to a solid pharmaceutical tablet comprising telithromycin or a salt thereof as an active ingredient in combination with a plasticizing effective amount of a microcrystalline cellulose diluent having a plastic behavior. Optional ingredients include a binder, a disintegrating agent and a lubricant, and the tablet may be optionally coated with a film-coating agent.Type: GrantFiled: August 30, 2013Date of Patent: February 24, 2015Assignee: Aventis Pharma SAInventor: Christian Desesquelle
-
Publication number: 20150044297Abstract: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralised acid.Type: ApplicationFiled: October 27, 2014Publication date: February 12, 2015Inventors: Karim Ioualalen, Rose-Anne Raynal
-
Patent number: 8951977Abstract: This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-one or roxithromycin characterized by the absence of peaks in the infra-red spectrum of amorphous (Form-I11) of roxithromycin at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 relative to the infra-red spectrum of the prior art roxithromycin raw material displaying peaks at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 and further characterized by an increased solubility of at least 50% over prior art anhydrous and monohydrated roxithromycin in acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water.Type: GrantFiled: April 14, 2011Date of Patent: February 10, 2015Assignee: North-West UniversityInventors: Wilna Liebenberg, Marique Aucamp
-
Publication number: 20150038851Abstract: Provided herein are methods of diagnosing meibomian gland dysfunction (MGD), determining the severity of meibomian gland dysfunction in a subject, evaluating efficacy of treatment of MGD in a subject, selecting a subject for treatment of MGD, and selecting a subject for participation in a clinical study.Type: ApplicationFiled: February 21, 2013Publication date: February 5, 2015Inventors: Pedram Hamrah, Yureeda Qazi
-
Publication number: 20150038439Abstract: A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: Steven K. MacLeod, Daniel J. Stein, James Donald Hayes, Donald L. Herber
-
Publication number: 20150038438Abstract: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.Type: ApplicationFiled: August 29, 2012Publication date: February 5, 2015Inventors: Arthur Branstrom, Vara Prasad Venkata Nagendra Josyula, Michael Andrew Arnold, Aleksey I. Gerasyuto, Gary Karp, Jiashi Wang, Guangming Chen, Olya Ginzburg, Song Huang, Jana Narasimhan, Srinivasa Peddi, Sean Wesley Smith, Anthony Allan Turpoff, Matthew G. Woll, Nanjing Zhang, Xiaoyan Zhang
-
Publication number: 20150038437Abstract: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.Type: ApplicationFiled: August 29, 2012Publication date: February 5, 2015Applicant: PTC THERAPEUTICS, INC.Inventors: Arthur Branstrom, Vara Prasad Venkata Nagendra Josyula, Michael Andrew Arnold, Aleksey I. Gerasyuto, Gary Karp, Jiashi Wang, John David Baird, Guangming Chen, Olya Ginzburg, Jana Narasimhan, Srinivasa Peddi, Hongyan Qi, Sean Wesley Smith, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang
-
Publication number: 20150017099Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.Type: ApplicationFiled: January 25, 2013Publication date: January 15, 2015Inventors: Noam A. Cohen, Robert J. Lee, Danielle R. Reed
-
Publication number: 20150010638Abstract: It is an object of the present invention to provide a method for improving the solubility of a poorly-soluble substance, which is capable of increasing the solubility of substantially all poorly-soluble substances. This is a method comprising coating the surface of a poorly-soluble substance particle with microparticles of a calcium compound such as calcium phosphate or calcium carbonate, and at least one selected from a pH adjuster and a surfactant, by applying mechanical energy thereto.Type: ApplicationFiled: February 21, 2013Publication date: January 8, 2015Inventors: Shuji Sakuma, Keiichiro Kikukawa, Ryosuke Miyasaka
-
Publication number: 20150011488Abstract: Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins are applied (A) directly to a genital wart in the form of a cream, ointment, paste or solution, (B) directly to the genital wart wherein such cream, ointment, paste or solution contains as an additional active ingredient a skin permeabilizing agent, (C) following electrosurgical resection or removal of the genital wart in such form of a cream, ointment, paste or solution, (D) following chemical resection or extirpation of the genital wart in such form, (E) following surgical resection or removal of the genital wart in such form, wherein said Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins both provide antiviral activity against multiple strains of human pappilomavirus (HPV) and promote healing following resection polymers contained in a vehicle. Disclosed are the compositions, therapeutical kits containing such composition, methods of treatment using such composition, and methods of enhancing the stability of such composition.Type: ApplicationFiled: March 10, 2014Publication date: January 8, 2015Applicant: CACAO BIO-TECHNOLOGIES, LLCInventors: Daniel PRESTON, Randall B. MURPHY
-
Publication number: 20150004216Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.Type: ApplicationFiled: September 19, 2014Publication date: January 1, 2015Inventor: Robert Steven Davidson
-
Publication number: 20150005248Abstract: The present invention relates to methods for culturing spirochetes, in particular Borrelia burgdorferi. The present invention also provides methods of identifying spirochetes present in a biological sample. The present invention further provides methods of diagnosing diseases cause by a spirochete infection, such as Lyme disease, syphilis, and multiple sclerosis. The present invention further provides methods for identifying spirochete susceptibilities to antimicrobials and antimicrobial compositions and cocktails. The present invention also provides methods for treating subjects suspected of having a spirochete infection.Type: ApplicationFiled: July 23, 2014Publication date: January 1, 2015Inventors: Eva T. Sapi, Timothy R. Schwartz, Namrata Pabbati
-
Publication number: 20140378401Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.Type: ApplicationFiled: December 18, 2013Publication date: December 25, 2014Applicant: GNT, LLCInventor: Gerald Horn
-
Publication number: 20140377327Abstract: Contact lenses are described that include particles of polymer fiber mat incorporated into a polymer lens wherein the polymer fiber mat is formed by electrospinning a prepolymer solution. Methods for making the contact lenses with improved oxygen permeability are also described. Methods for making the contact lens with optional therapeutic drug delivery and refractive correction are also described.Type: ApplicationFiled: June 19, 2014Publication date: December 25, 2014Inventors: Keela Davis, Martin Reuter, Anthony Kammerich, Andrew Tangonan, Kumar Vedantham, Anna Kelley
-
Publication number: 20140371134Abstract: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.Type: ApplicationFiled: June 18, 2013Publication date: December 18, 2014Inventor: Jay Richard Ray, II
-
Publication number: 20140366872Abstract: A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nose, the osteomeatal complex or a paranasal sinus. The pressure of the aerosol is not constant, but pulsates at a frequency from about 10 to 90 Hz. The aerosol is further characterised in that it exhibits a low effective flow rate of less than about 5 litres per minute. The aerosol is, inter alia, suitable for the prevention, management, or treatment of a disease, symptom, or condition affecting the nose or the paranasal sinuses, such as acute and chronic sinusitis.Type: ApplicationFiled: August 27, 2014Publication date: December 18, 2014Inventors: Manfred Keller, Uwe Schuschnig, Johann Zimmermann, Martin Luber, Andreas Böhm
-
Publication number: 20140364383Abstract: Methods and materials useful for applying pharmacologic agents to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and at least one pharmacologic agent to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the tympanic membrane in a flowable form and, after delivery to the tympanic membrane, becomes sufficiently viscous such that the pharmacologic agent is localized against the tympanic membrane. Such compositions can be used to prophylactically and/or therapeutically treat middle and inner ear conditions, including otitis media.Type: ApplicationFiled: May 21, 2014Publication date: December 11, 2014Applicant: Regents of the University of MinnesotaInventors: Ronald J. Sawchuk, Belinda W.Y. Cheung
-
Publication number: 20140357586Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Inventor: Mahesh V. Patel
-
Publication number: 20140356457Abstract: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test comType: ApplicationFiled: April 7, 2014Publication date: December 4, 2014Applicant: UNIVERSITY OF GENEVAInventors: Karl-Heinz KRAUSE, Botond BANFI
-
Patent number: 8901089Abstract: The invention relates to an amorphous non-crystalline glass form (Form-II) of 3R,4S,5S,6R,7R,9R,11S,12R,13S,14R-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxa-cyclotetradecan-2-one or roxithromycin having at least one characteristic infra-red spectrum peak at approximately 3580 to 3464 cm?1. The invention further relates to a preparation method of increasing the solubility of roxithromycin including the steps of selecting anhydrous roxithromycin or monohydrated roxithromycin; elevating the temperature of the roxithromycin to above the melting point thereof; and reducing the temperature of the melt sufficiently to allow it to set into an amorphous non-crystalline glass form (Form-II) of roxithromycin having relatively increased solubility without decreasing the stability of thereof.Type: GrantFiled: December 15, 2010Date of Patent: December 2, 2014Assignee: North-West UniversityInventors: Wilna Liebenberg, Marique Aucamp, Melgardt M De Villiers
-
Publication number: 20140343003Abstract: The present invention provides a method for treating Lyme disease and/or a Borrelia infection in animals comprising administering to an animal in need thereof a therapeutically effective amount of cefovecin.Type: ApplicationFiled: December 20, 2012Publication date: November 20, 2014Inventors: Patrick F. M. Meeus, Christopher L. Haber
-
Patent number: 8889733Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.Type: GrantFiled: January 14, 2013Date of Patent: November 18, 2014Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul Wahab, Christian D. A. Fozing, Atta-ur Rahman
-
Publication number: 20140328917Abstract: An organic compound nano-powder comprising a granular organic compound with an average particle diameter of 500 nm or less and a 90%-diameter of less than 1500 nm and a carbohydrate compound comprising at least any one of a sugar and a sugar alcohol and with amount of 0.3 times or more by mass relative to amount of the organic compound, a method for producing the same, and a suspension having the organic compound dispersed in a liquid dispersion medium in which the organic compound is insoluble or poorly soluble.Type: ApplicationFiled: May 11, 2013Publication date: November 6, 2014Inventors: Takahiro Tada, Kazuhiro Kagami, Shiro Yokota
-
Publication number: 20140323419Abstract: The invention teaches a method for treatment of Helicobacter pylori infection and a packaging system for the distribution, use and implementation of the treatment method.Type: ApplicationFiled: April 24, 2014Publication date: October 30, 2014Inventor: TAT-KIN TSANG
-
Patent number: 8871728Abstract: Compounds of Formula I or II, and methods of making and using thereof, are described herein. M represents a macrolide subunit, E is a C1-6 group, optionally containing one or more heteroatoms, D is an alkyl or aryl group, A is a linking group connected to D, B is an alkyl, alkylaryl or alkylheteroaryl spacer group, ZBG is a Zinc Binding Group, R1, R2 and R4 are independently are selected from hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkanoate group, a C2-6 carbamate group, a C2-6 carbonate group, a C2-6 carbamate group, or a C2-6 thiocarbamate group, R3 is hydrogen or —OR5, R5 is selected from a group consisting of Hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, C1-6 alkanoate group, C2-6 carbamate group, C2-6 carbonate group, C2-6 carbamate group, or C2-6 thiocarbamate group.Type: GrantFiled: May 25, 2012Date of Patent: October 28, 2014Assignee: Georgia Tech Research CorporationInventors: Adegboyega Oyelere, Subhasish Tapadar
-
Publication number: 20140314847Abstract: The present invention provides a controlled release oral pharmaceutical composition having a therapeutically effective amount of one or more pharmacologically active agent having low bioavailability; one or more solubilizers; one or more biocompatible swelling agents; and a swelling enhancer. The swelling agent, in combination with swelling enhancer, swells in the presence of water in gastric fluid such that the size of the dosage form is sufficiently increased to provide retention of the dosage form in the stomach of a patient, which gradually erodes within the gastrointestinal tract over a prolonged time period.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Pratibha S. PILGAONKAR, Maharukh T. RUSTOMJEE, Anilkumar S. GANDHI, Pradnya M. BAGDE
-
Publication number: 20140315841Abstract: Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.Type: ApplicationFiled: May 7, 2014Publication date: October 23, 2014Applicant: Red Hill Biopharma Ltd.Inventors: Thomas Julius Borody, Patrick Gosselin
-
Patent number: 8865662Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.Type: GrantFiled: August 13, 2010Date of Patent: October 21, 2014Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Patent number: 8858965Abstract: The invention provides active agents, such as paclitaxel, rapamycin, or 17-DMAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-DMAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.Type: GrantFiled: August 30, 2013Date of Patent: October 14, 2014Assignee: Wisconsin Alumni Research FoundationInventor: Glen S. Kwon
-
Publication number: 20140296172Abstract: A method of screening compounds or molecules comprising the steps of: translating a sequence encoding the amino acid sequence comprising SEQ ID No. 29 in a translation system in the presence of a test compound or molecule; and analysing the translation product(s) for the presence of one or more of (a) a peptide comprising the amino acids Pro-Gly at the C terminus and a peptide comprising the amino acid Pro at the N terminus: or (b) a peptide comprising the amino acid sequence of SEQ ID No. 29.Type: ApplicationFiled: September 23, 2013Publication date: October 2, 2014Applicants: UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS, UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORKInventors: John Fuller Atkins, Martin Ryan, Gary Loughran
-
Publication number: 20140286931Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventor: Chengzhi Zhang
-
Patent number: 8841263Abstract: The present invention provides macrocyclic compounds useful as therapeutic agents of the formula: or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R1, R2, R3, D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.Type: GrantFiled: June 18, 2012Date of Patent: September 23, 2014Assignee: Melinta Therapeutics, Inc.Inventors: Jay J. Farmer, Ashoke Bhattacharjee, Yi Chen, Joel A. Goldberg, Joseph A. Ippolito, Zoltan F. Kanyo, Rongliang Lou, Adegboyega K. Oyelere, Edward C. Sherer, Joyce A. Sutcliffe, Deping Wang, Yusheng Wu, Yanming Du
-
Publication number: 20140271921Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.Type: ApplicationFiled: May 28, 2014Publication date: September 18, 2014Applicant: SLA PHARMA AGInventor: DAVID NIGEL ARMSTRONG
-
Publication number: 20140271701Abstract: The present invention concerns antibodies recognizing Mycobacterium avium paratuberculosis epitopes able to cross-reacting with the beta-cell antigen ZnT8 to be used as early biomarkers of type 1 diabetes, epitopes for in vitro prognostic and diagnostic methods suitable to reveal a risk to develop type 1 diabetes, therapies for the prevention of T1D by avoiding, controlling or monitoring Mycobacterium paratuberculosis infection.Type: ApplicationFiled: October 25, 2012Publication date: September 18, 2014Inventors: Leonardo Antonio Sechi, Roberto Mallone
-
Publication number: 20140274925Abstract: Disclosed herein are compositions and methods for diagnosing, treating, and monitoring Lyme disease.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: Chenggang Jin, Gottfried H. Kellermann
-
Publication number: 20140274924Abstract: Provided is concentrated aqueous azithromycin formulation from about from about 2%-20%, and a method of making a concentrated aqueous azithromycin formulation which includes preparing and sterilizing a first solution comprising a strong base to form a sterilized solution, dissolving the azithromycin in an aqueous solution comprising an acid consisting essentially of a strong acid, and adding the aqueous solution comprising the strong acid to the sterilized solution comprising the strong base. The strong acid has a pKa less than about ?1.74 and the method is carried out without addition or use of a weak acid.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: INSITE VISION INCORPORATEDInventors: Lyle M. Bowman, Sui Yen Eddie Hou, Tang Nguyen
-
Patent number: 8835376Abstract: A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution; (b) providing an excipient to at least one of the precipitant solution, the anti-solvent solution and the suspension of drug nanoparticles, the excipient being selected to maintain said drug nanoparticles in a dispersed state when in liquid form; and (c) drying the suspension of drug nanoparticles containing the excipient therein to remove solvent therefrom, wherein removal of the solvent causes the excipient to solidify and thereby form micro-sized matrix particles, each micro-sized particle being comprised of drug nanoparticles dispersed in a solid matrix of the excipient.Type: GrantFiled: September 24, 2009Date of Patent: September 16, 2014Assignee: Nanomaterials Technology Pte LtdInventors: Zhigang Shen, Jimmy Sung Lai Yun, Jun Hu, Nital Arvind Jugade, Jiyao Zhang, Wenhao Chen, Zhe Wang, Lingyan Gao, William Glover, Jian Feng Chen
-
Publication number: 20140256661Abstract: The present invention relates to a pharmaceutical composition, in particular a composition formulated for enema administration, wherein the composition comprises metronidazole or a pharmacologically acceptable derivative thereof in an amount to effectively treat both acute and chronic pouchitis and/or proctitis.Type: ApplicationFiled: July 12, 2012Publication date: September 11, 2014Inventor: David Nigel Armstrong
-
Publication number: 20140256616Abstract: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Applicant: Georgia Regents Research Institute, Inc.Inventor: Stephen D. Hsu
-
Publication number: 20140255342Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Applicants: TIANJIN HEMAY BIO-TECH CO., LTD., TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTDInventors: Hesheng Zhang, Guanghuai Zeng, Yifei Gao
-
Publication number: 20140243279Abstract: A composition of the present invention comprises an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, wherein the effective amount of the absorption enhancer is sufficient so that, when the composition is administered to a patient, an overall metabolism of clarithromycin as caused by rifabutin is reduced by shifting competing metabolism of rifabutin and clarithromycin so as to result in more active clarithromycin.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: Red Hill Biopharma Ltd.Inventors: Thomas Julius Borody, Patrick Gosselin
-
Patent number: 8815831Abstract: The invention provides a method to improve the efficacy of an antibiotic to inhibit the growth of Acinetobacter, said method comprising using said antibiotic together with an alginate oligomer. The Acinetobacter may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with Acinetobacter. In another aspect the method can be used to combat Acinetobacter contamination of a site e.g., for disinfection and cleaning purposes.Type: GrantFiled: June 3, 2010Date of Patent: August 26, 2014Assignee: Algipharma ASInventors: Edvar Onsoyen, Rolf Myrvold, Arne Dessen, David Thomas, Timothy Rutland Walsh
-
Publication number: 20140234420Abstract: The present invention describes methods and compositions for treating diverse dermatological conditions, including acne and psoriasis, using zein containing nanocarrier devices for topical delivery of methotrexate, retinoic acid and benzoyl peroxide to select targets in the skin.Type: ApplicationFiled: August 14, 2013Publication date: August 21, 2014Inventors: Omathanu P. Perumal, Ranjith Kumar Averineni
-
Publication number: 20140228307Abstract: A combination of antibiotics including rifabutin, clarithromycin and clofazimine for the treatment of an autoimmune disease such as multiple sclerosis and related diseases. In a further aspect, there is provided a composition comprising a combination of two or more antibiotic agents for the treatment of an autoimmune disease, said two or more antibiotic agents selected from rifabutin, clofazimine, and at least one macrolide.Type: ApplicationFiled: September 19, 2012Publication date: August 14, 2014Inventors: Reza Fathi, Patrick Laughlin McLean, Harry Jefferson Leighton
-
Patent number: 8796232Abstract: Triazole-containing macrolide and ketolide antibiotics, therapeutic compositions containing them and methods of use for treating diseases caused by one or more resistant organisms are described.Type: GrantFiled: October 24, 2009Date of Patent: August 5, 2014Assignee: Cempra Pharmaceuticals, Inc.Inventors: Prabhavathi B. Fernandes, David E. Pereira
-
Publication number: 20140212490Abstract: A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: SHIONOGI INC.Inventors: Bruce Cao, Sandra E. Wassink, Donald J. Treacy, JR., Beth A. Burnside, Colin E. Rowlings, John A. Bonck
-
Patent number: 8791080Abstract: Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.Type: GrantFiled: October 24, 2009Date of Patent: July 29, 2014Assignee: Cempra Pharmaceuticals, Inc.Inventor: Prabhavathi B. Fernandes
-
Publication number: 20140206633Abstract: The present invention relates to processes for the preparation of compounds of formula IB wherein A1, A2, A3, A4, L, Y1, Y2, R1, R2, R3, R4 and R5 are as defined in the claims, comprising reacting a compound of formula (II) wherein Y1, Y2, L, A1, A2, R1, R2, R3, R4 and R5 are as defined for the compound of formula (I); with hydroxylamine in the presence of water, a base and a chiral phase transfer catalyst, which chiral phase transfer catalyst is a quinine derivative. The invention also relates to compounds of formula IB and enantiomerically enriched mixtures comprising compounds of formula IB.Type: ApplicationFiled: February 3, 2011Publication date: July 24, 2014Applicant: SYNGENTA CROP PROTECTION LLCInventors: Nicholas Phillip Mulholland, Edouard Godineau, Jérôme Yves Cassayre, Peter Renold, Myriem El Qacemi, Guillaume Revol